1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

Prospects For Leading Players

Report Details

Vaccine manufacturing technology and services - your guide to trends and revenue prospects for vaccine production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:
- Paediatric vaccines
- Influenza vaccines
- Adult prophylactic vaccines
- Therapeutic vaccines
- Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects for vaccine contract manufacturing in the leading regions and countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:
- US
- Japan
- Germany
- Italy
- Spain
- France
- UK
- Russia
- China
- India
- Brazil
- RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
- Baxter BioPharma Solutions
- Boehringer Ingelheim
- Catalent
- Charles River Laboratories
- IDT Biologika GmbH
- Lonza
- Meridian Life Science
-

Table Of Contents

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
1. Executive Summary
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods

2. Introduction to the Vaccine Market
2.1 What Are Vaccines?
2.2 The History of the Vaccine Market
2.3 The Vaccine Contract Manufacturing Market
2.3.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
2.3.2 Reasons to Outsource
2.3.3 Benefits of Outsourcing
2.3.4 The Challenges in Outsourcing Vaccine Manufacturing
2.3.5 Why Should Companies Outsource Vaccine Manufacturing?
2.3.6 Strategic Outsourcing vs. Tactical Outsourcing
2.3.7 Virtual Companies
2.3.8 Contract Manufacturing Organisations (CMOs)
2.3.9 Manufacturing Services Offered by CMOs
2.3.10 Vaccine Manufacturing Activities Typically Outsourced

3. Vaccine Manufacturing Technologies 2014
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift Towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax's Sf9/BV Technology
3.2.6.2 Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2014
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Novartis' Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.7 Cell Media Can Improve Virus Yield

4. The Vaccine Market 2014-2024
4.1 The Global Vaccine Market, 2014-2024
4.2 The Global Vaccine Market By Submarket, 2012 and 2013
4.3 The Global Vaccine Market by Submarket, 2014-2024
4.4 The Paediatric Vaccine Submarket Forecast, 2014-2024
4.4.1 Growth of Paediatrics Vaccines is Driven by Prevnar's Blockbuster Success
4.4.2 Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
4.4.3 Paediatric Vaccine Pipeline
4.5 The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
4.5.1 Adult Vaccination: Low Uptake
4.5.2 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
4.5.3 Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
4.5.4 Adult Prophylactic Vaccine Pipeline
4.6 The Influenza Vaccine Submarket, 2014-2024
4.6.1 Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
4.6.2 Significant Scope for Enlarging the Patient Population
4.6.3 Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
4.6.4 Influenza Product Pipeline
4.7 The Therapeutic Vaccine Submarket, 2014-2024
4.7.1 Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
4.7.2 Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
4.7.2.1 Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
4.7.2.3 Biovac ID Completes Phase III for Cancer Vaccine
4.7.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
4.7.3.1 Canada Gives Merck and Co. its First Approval for Grass Allergy Vaccine Tablet
4.7.3.2 Therapeutic Vaccine Product Pipeline

5. The Global Vaccine Contract Manufacturing Market 2014-2024
5.1 Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
5.2 The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
5.2.1 Trends in the Vaccine Contract Manufacturing Forecast
5.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.3.1 The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
5.3.2 The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
5.3.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.4 The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5 The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5.1 CMO's in Japan
5.6 The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
5.6.1 The EU5 Vaccine Contract Manufacturing Market, 2014-2024
5.6.2 The French Vaccine Contract Manufacturing Market, 2014-2024
5.6.3 The German Vaccine Contract Manufacturing Market, 2014-2024
5.6.4 The Italian Vaccine Contract Manufacturing Market, 2014-2024
5.6.5 The Spanish Vaccine Contract Manufacturing Market, 2014-2024
5.6.6 The UK Vaccine Contract Manufacturing Market, 2014-2024
5.7 The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
5.8 The Russian Vaccine Contract Manufacturing Market, 2014-2024
5.9 The Indian Vaccine Contract Manufacturing Market, 2014-2024
5.10 The Chinese Vaccine Contract Manufacturing Market, 2014-2024
5.10.1 Vaccine Manufacturing: Questioning China's Regulatory Standards

6. The Leading Vaccine Contract Manufacturing Companies 2014-2024
6.1 The Vaccine Contract Manufacturing Market has Room for Consolidation
6.2 Baxter BioPharma Solutions
6.2.1 Business Capabilities
6.3 Boehringer Ingelheim
6.3.1 Recent Financial Performance
6.3.2 Boehringer Ingelheim's Ben Venue Closure
6.3.3 Manufacturing Deals 2011-2014
6.3.4 Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
6.3.5 Boehringer Ingelheim Expands Biopharmaceuticals in China
6.3.6 Outlook
6.4 Catalent
6.4.1 Recent Financial Performance, 2008-2012
6.4.2 Recent Financial Performance by Segment, 2008-2012
6.4.3 Catalent Injectable Vaccines
6.4.4 Catalent Adjusts its Services
6.4.5 Future Strategies for Growth
6.4.6 Regional Market Expansion
6.5 Charles River Laboratories
6.5.1 Recent Financial Performance, 2008-2012
6.5.2 Recent Financial Performance, 3Q 2013
6.5.3 Recent Financial Performance by Segment
6.5.4 Vaccine Manufacturing Services
6.5.4.1 Vaccine Manufacturing Expansion
6.5.5 Future Outlook and Early Stage Restructuring
6.5.6 Partnerships
6.5.6.1 Partnership with AstraZeneca
6.5.6.2 Partnership with Batavia
6.6 IDT Biologika GmbH
6.6.1 Facility Expansion
6.6.2 Acquisitions and Partnerships
6.6.2.1 Acquisition of Riemser Pharma GmbH
6.6.2.2 Partnership with ImVisioN Therapeutics
6.7 Lonza
6.7.1 Recent Financial Performance, 2010-2012
6.7.1.1 Recent Financial Performance by Segment,2012
6.7.2 Manufacturing Division Restructuring
6.8 Meridian Life Science
6.8.1 Recent Financial Performance, 2008-2013
6.8.1.1 Recent Financial Performance by Segment, 2008-2013
6.8.1.2 Recent Financial Performance by Region, 2012-2013
6.9 Sigma-Aldrich
6.9.1 Revenue and Recent Performance Analysis, 2010-2013
6.9.1.1 Recent Financial Performance by Segment, 2010-2012
6.9.1.2 Segment restructuring, 2013
6.9.2 Strategy for Business Growth by Asian Expansion
6.9.3 Acquisition of BioReliance
6.9.4 Partnership with CatScl
6.10 SynCo Bio Partners
6.10.1 Recent Developments
6.10.1.1 Expansion of Facilities
6.10.1.2 FDA Approval of Partner Application
6.11 OSO BioPharmaceuticals Manufacturing
6.11.1 Facilities and Capabilities
6.11.2 New Developments
6.11.2.1 Acquisition of Catalent's Sterile Injectables Manufacturing Business
6.11.2.2 Facility Investment
6.12 Leading Vaccine Contract Manufacturing Organisations

7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024
7.1 Vaccine Contract Manufacturing Industry Trends
7.2 Strengths
7.2.1 Many Companies Cannot Afford In-house Capabilities
7.2.2 Outsourcing Improves Time to Market
7.2.3 Manufacturers get Access to Specialised Technologies
7.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
7.3 Weaknesses
7.3.1 Mass Vaccine Manufacturing is Kept In-house
7.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
7.3.3 An Unpredictable Supply and Demand Business Model
7.3.4 Lack of Differentiation in the CMO Space
7.4 Opportunities
7.4.1 Many Vaccines in the Product Pipeline
7.4.2 Therapeutic Vaccine Market could Explode
7.4.3 Emerging Market's Growing Demand for Vaccines
7.4.3.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
7.5 Threats
7.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
7.5.2 The Public are Slow to Accept Novel Technologies
7.5.3 Perception of Risk by the Original Vaccine Manufacturers

8. Expert Opinion
8.1 Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
8.1.1 The Egg-based Vaccine Manufacturing Myth
8.1.2 AfriVax's New Vaccine Manufacturing Technology
8.1.3 Emerging Markets Pathing their Own Vaccine Path
8.2 Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
8.2.1 Growth of the Vaccine Contract Manufacturing Market
8.2.2 The Therapeutic Vaccine Market
8.2.3 The Use of Emerging Market Facilities
8.2.4 The Vaccine Contract Manufacturing Business Model
8.3 Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing and Research and Development (RandD), Meridian Life Science
8.3.1 Vaccine Contract Manufacturing Competition
8.3.2 Target Diseases For Vaccine Development
8.3.3 Challenge Stock Vaccines
8.3.4 Meridian's Vaccine Contract Manufacturing Revenue Stream Breakdown
8.3.5 The Changing Face of Large Pharma Drives Contract Manufacturing Growth
8.4 Interview with Dr Stefan Beyer, Managing Director, Vibalogics
8.4.1 The Benefits of Outsourcing Vaccine Manufacturing
8.4.2 The Challenges in Manufacturing Vaccines

9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Rich Pipeline for Therapeutic Vaccines
9.4 Emerging Markets will Show Stronger Growth
9.5 Technology Drives Changes in Manufacturing

List of Tables
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
Table 3.1 Vaccine Development Pipeline Using Protein Sciences Corporation's BEVS Vaccine Technology, 2014
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2014
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2014
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2014
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2014
Table 3.6 Prominent Lyophilised Vaccines, 2014
Table 3.7 Examples of Serum-free Media for Vaccine Manufacturing, 2014
Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.2 The Global Vaccine Market: Revenue ($bn), Market Share by Submarket (%), 2012-2013
Table 4.3 The Global Vaccine Market by Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.4 The Paediatric Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.5 Selected Pipeline Vaccines in Paediatric Submarket, 2014
Table 4.6 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.7 Selected Pipeline Vaccines in Adult Prophylactic Submarket, 2014
Table 4.8 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.9 Selected Pipeline Vaccines in Influenza Submarket, 2014
Table 4.10 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.11 Selected Pipeline Vaccines in Therapeutic Submarket, 2014
Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.2 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), Market Share (%), 2012-2013
Table 5.3 The Leading National Vaccine Contract Manufacturing Markets Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.4 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.5 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.6 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m), Market Share (%) by Country, 2012-2013
Table 5.7 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.9 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.10 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.11 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.12 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.13 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.14 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.15 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.16 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.1 Baxter BioPharma Solutions Capabilities, 2014
Table 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Table 6.3 Catalent: Offerings and Services by Segment, 2014
Table 6.4 Catalent: Revenue($m), AGR (%), 2008-2012
Table 6.5 Catalent by Segment: Revenue($m), AGR (%), 2011-2012
Table 6.6 Charles River Laboratories: Services Provided by Segment, 2014
Table 6.7 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Table 6.8 Charles River Laboratories: Pre-clinical Services Segment Revenue ($m), 3Q 2012-2013
Table 6.9 Charles River Laboratories: Revenue ($bn) by Segment, 2009-2012
Table 6.10 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2014
Table 6.11 IDT: Work Units in the Vaccine Production Line
Table 6.12 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Table 6.13 Lonza: Revenue ($bn), Market Share (%) by Segment, 2012
Table 6.14 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Table 6.15 Meridian Bioscience: Revenue ($m), AGR (%) by Segment, 2010-2013
Table 6.16 Meridian Life Science: Revenue ($m), AGR (%) by Region, 2012-2013
Table 6.17 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2012
Table 6.18 Sigma Aldrich: Revenue ($bn) by Segment, 2010-2012
Table 6.19 SynCo's Capabilities, 2014
Table 6.20 Leading Vaccine Contract Manufacturing Organisations, 2014
Table 7.1 SWOT Analysis of the Vaccine Contract Manufacturing Market, 2012-2024

List of Figures
Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2014
Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2014
Figure 3.2 Medicago's Product Pipeline, 2014
Figure 3.3 Novavax' Insect Egg-Based Vaccine Production Process, 2014
Figure 3.4 Novavax's Product Pipeline, 2014
Figure 3.5 Single-Use Bioreactors Market, 2012
Figure 3.6 Pre-filled Syringes Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2012-2024
Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2013
Figure 4.3 The Paediatric Vaccine Market: Revenue ($bn), AGR (%), 2012-2024
Figure 4.4 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.5 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.6 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.2 The Leading National Vaccine Contract Manufacturing Markets: Revenue (%) by region, 2013
Figure 5.3 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.4 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.5 The EU5 Vaccine Contract Manufacturing Markets: Revenue (%) by Country, 2013
Figure 5.6 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.7 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.8 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.9 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.10 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.11 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.12 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.14 The Indian Vaccines Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.15 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 6.1 Boehringer Ingelheim: Typical Contract Manufacturing Process, 2014
Figure 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Figure 6.3 Catalent: Revenue ($m), AGR (%), 2008-2012
Figure 6.4 Catalent: Market Share (%) by Segment, 2012
Figure 6.5 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Figure 6.6 Charles River Laboratories: Revenue ($bn), AGR (%), 3Q 2012-2013
Figure 6.7 Charles River Laboratories: Market Share (%) by Segment, 2012
Figure 6.8 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Figure 6.9 Lonza: Market Share (%) by Segment, 2012
Figure 6.10 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Figure 6.11 Meridian Bioscience: Revenue ($m) by Segment, 2010-2013
Figure 6.12 Meridian Bioscience: Market Share (%) by Segment,2013
Figure 6.13 Meridian Life Science: Market Share by Region, 2013
Figure 6.14 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2013
Figure 6.15 Sigma Aldrich: Market Share (%) by Segment, 2012
Figure 6.16 Sigma Aldrich: Market Share (%) by Segment, 2013
Figure 7.1 Vaccines in the Pipeline, Phase 1-3
Figure 7.2 Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2014-2024
Figure 9.1 Vaccine and Vaccine Contract Manufacturing Market: AGR(%), 2012-2024
Figure 9.2 Therapeutic Vaccines in the Pipeline, Phase 1-3

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.